HM2018-13 :A GLOBAL RANDOMIZED MULTICENTER PHASE 3 TRIAL TO COMPARE THE EFFICACY ANDSAFETY OF JCAR017 TO STANDARD OF CARE IN ADULT SUBJECTS WITH HIGH-RISK, TRANSPLANTELIGIBLE RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMAS(TRANSFORM)

Project: Research project

Project Details

Description

HM2018-13 :A GLOBAL RANDOMIZED MULTICENTER PHASE 3 TRIAL TO COMPARE THE EFFICACY AND SAFETY OF JCAR017 TO STANDARD OF CARE IN ADULT SUBJECTS WITH HIGH-RISK, TRANSPLANT ELIGIBLE RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMAS (TRANSFORM)
StatusActive
Effective start/end date7/25/187/30/23

Funding

  • Celgene Corporation

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.